Literature DB >> 23355216

Mycophenolate mofetil has potent anti-inflammatory actions in a mouse model of acute lung injury.

M G Beduschi1, C L Guimarães, Z S Buss, E M Dalmarco.   

Abstract

Septic shock is a systemic inflammatory response syndrome, and it is the leading cause of death in intensive care units. Mycophenolate mofetil (MMF) is an immunosuppressant that has been shown to be effective in the treatment of various inflammatory diseases. In this study, the anti-inflammatory effect of MMF in a mouse model of acute lung injury (ALI) induced by lipopolysaccharide (LPS) was evaluated. ALI was induced by intrapleural injection of LPS (250 ng/cavity). The leukocyte migration, exudation, myeloperoxidase and adenosine deaminase activities, nitric oxide products, tumor necrosis factor alpha (TNF-α), and interleukin 1 beta (IL-1β) levels, as well as mRNA expression of TNF-α and IL-1β, were evaluated. This study showed that MMF significantly decreased all parameters studied in a manner comparable to treatment with dexamethasone. In conclusion, MMF has important anti-inflammatory effects that may be useful as an auxiliary treatment for septic shock.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355216     DOI: 10.1007/s10753-013-9599-x

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  30 in total

1.  Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Authors:  Shin-Ichi Hayashi; Takayuki Yamada; Motokazu Tsuneto; Toshiyuki Yamane; Masayuki Takahashi; Leonard D Shultz; Hidetoshi Yamazaki
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

Review 2.  Severe sepsis and septic shock: review of the literature and emergency department management guidelines.

Authors:  H Bryant Nguyen; Emanuel P Rivers; Fredrick M Abrahamian; Gregory J Moran; Edward Abraham; Stephen Trzeciak; David T Huang; Tiffany Osborn; Dennis Stevens; David A Talan
Journal:  Ann Emerg Med       Date:  2006-05-02       Impact factor: 5.721

Review 3.  Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection.

Authors:  Anthony C Allison; Elsie M Eugui
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

4.  A glycoprotein from Porphyra yezoensis produces anti-inflammatory effects in liposaccharide-stimulated macrophages via the TLR4 signaling pathway.

Authors:  Eun-Soon Shin; Hye-Jung Hwang; In-Hye Kim; Taek-Jeong Nam
Journal:  Int J Mol Med       Date:  2011-06-23       Impact factor: 4.101

5.  Evidence of an anti-inflammatory effect of mycophenolate mofetil in a murine model of pleurisy.

Authors:  Eduardo Monguilhott Dalmarco; Caio Maurício Mendes de Córdova; Tânia Silvia Fröde
Journal:  Exp Lung Res       Date:  2011-07-21       Impact factor: 2.459

Review 6.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; M M Levy
Journal:  Intensive Care Med       Date:  2004-03-03       Impact factor: 17.440

Review 8.  Myeloperoxidase and its contributory role in inflammatory vascular disease.

Authors:  Denise Lau; Stephan Baldus
Journal:  Pharmacol Ther       Date:  2006-02-13       Impact factor: 12.310

9.  Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

Authors:  A Sinclair; G Appel; M A Dooley; E Ginzler; D Isenberg; D Jayne; D Wofsy; N Solomons
Journal:  Lupus       Date:  2007       Impact factor: 2.911

10.  Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Authors:  Chad Heatwole; Emma Ciafaloni
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more
  3 in total

1.  1,8-cineol attenuates LPS-induced acute pulmonary inflammation in mice.

Authors:  Chunzhen Zhao; Jianbo Sun; Chunyan Fang; Fadi Tang
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

2.  Mycophenolate Mofetil Protects Septic Mice via the Dual Inhibition of Inflammatory Cytokines and PD-1.

Authors:  Shun-Wei Huang; Hao Chen; Mei-Ling Lu; Jin-Long Wang; Rong-Li Xie; Bing Zhao; Ying Chen; Zhi-Wei Xu; Jian Fei; En-Qiang Mao; Er-Zhen Chen
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

3.  A Novel Curcumin-Mycophenolic Acid Conjugate Inhibited Hyperproliferation of Tumor Necrosis Factor-Alpha-Induced Human Keratinocyte Cells.

Authors:  Yonelian Yuyun; Pahweenvaj Ratnatilaka Na Bhuket; Wiwat Supasena; Piyapan Suwattananuruk; Kemika Praengam; Opa Vajragupta; Chawanphat Muangnoi; Pornchai Rojsitthisak
Journal:  Pharmaceutics       Date:  2021-06-25       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.